Compare Amphastar Pharmaceuticals Inc (AMPH) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Mongodb Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Mongodb Inc trades at $437.9 (market cap $33.51B). The key difference: Mongodb Inc is far larger — about 38.8× Amphastar Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | MDB | |
|---|---|---|
Market Cap | $863.95M | $33.51B |
Sector | Health | Technology |
52-Week High | $30.81 | $440.25 |
52-Week Low | $16.87 | $201.08 |
Enterprise Value | $1.26B | $31.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
MongoDB (MDB) trades at $398.8, up 7.78% in the last session, reflecting strong momentum near the consensus price target of $400.39. The stock shows bullish technical signals with support at $384 and resistance at $407. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent quarters have consistently beaten EPS estimates, and analyst sentiment is overwhelmingly positive with 82% buy ratings.
The outlook for MDB is optimistic due to accelerating revenue growth and AI-driven demand, but risks include persistent losses, high valuation multiples, and competitive pressures. Institutional buying and bullish technical trends support near-term upside, yet profitability challenges warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
